Overview
Biobot Analytics uses wastewater data to monitor public health. It collects samples from communities and analyzes them to track trends in health indicators such as viruses, bacteria, drug use, and foodborne pathogens. The results are delivered through subscriptions and service contracts as regular reports and real-time data dashboards for governments, businesses, universities, and health systems. Unlike many data providers, Biobot combines lab analysis with ongoing data services to turn sewage into actionable public health insights. Its goal is to turn wastewater infrastructure into a tool for public health surveillance, helping clients make informed decisions to improve community health and equity.
Work here?Claim your company
Simplify's take
What believers are saying
- White House ONDCP awarded Biobot a September 2025 contract for nationwide drug-trend monitoring.
- June 2026 Nature Water publication strengthens credibility for federal buyers and public health agencies.
- Lincoln and other cities keep expanding monitoring, creating repeat demand beyond COVID-era surveillance.
What critics are saying
- Massachusetts ends Biobot's $400,000 monthly contract July 31, 2026, cutting major recurring revenue.
- CDC replaced Biobot with Verily in 2023, proving federal customers face aggressive substitution.
- Governments increasingly insource wastewater testing, shrinking Biobot's moat and threatening eventual commoditization.
What makes BioBot Analytics unique
- Nationwide wastewater network spans 76 sites across 41 states, validated in Nature Water.
- Biobot delivers near-real-time signals months before overdose reporting, beating traditional surveillance timelines.
- Its dashboard detects many pathogens and substances from one sample, including fentanyl and xylazine.
Help us improve and share your feedback! Did you find this helpful?
